Inflammatory Breast Cancer Clinical Trial
Official title:
A Prospective, Randomized, Open-label Comparison of Preoperative Weekly Paclitaxel and Cisplatin With or Without Endocrine Therapy in Patients With Operable Hormone Receptor Positive and Triple Negative Locally Advanced Breast Cancer
The investigators hypothesize that paclitaxel combined with cisplatin in a weekly-based regimen as neoadjuvant chemotherapy is effective and tolerable for locally advanced breast cancer. In patients with some sub-type advanced breast cancer, neo-adjuvant chemotherapy combined with endocrine therapy may improve the pathological remission rate. Premenopausal patients with triple negative breast caner and hormonal receptor positve breast cancer patients will be randominzed to have neoadjuvant chemotherapy combined with endocrine therapy or not.
In this trial, patients with ER and or PR positive breast cancer will be separately randomized to have chemotherapy or chemotherapy combined with endocrine therapy according to their menstrual status. Letrozole for the postmenopausal women and ovarian function suppression for the premenopausal women. Patients with triple negative breast cancer will be randomized to have neoadjuvant chemotherapy combined with ovarian function suppression if she is premenopausal. Postermenopausal patients with triple negative breast caner will only have neoadjuvant chemotherapy. Patients with Her2 overexpression can obtain anti-Her2 target therapy. This study has been amended to a 1:2 ratio to control and neoadjuvant chemotherapy combination of endocrine therapy. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00344071 -
Pilot Study of Inflammatory Breast Cancer in Egypt and Tunisia
|
N/A | |
Recruiting |
NCT05383196 -
Onvansertib + Paclitaxel In TNBC
|
Phase 1/Phase 2 | |
Completed |
NCT02324088 -
Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer
|
Phase 3 | |
Completed |
NCT00003199 -
Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
|
Phase 2 | |
Terminated |
NCT00016276 -
Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer
|
Phase 3 | |
Recruiting |
NCT01880385 -
Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06131632 -
Conserving Surgery in Inflammatory Breast Cancer After Neoadjuvant Chemotherapy
|
N/A | |
Completed |
NCT00513695 -
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
|
Phase 2 | |
Completed |
NCT00340158 -
Establishing an Inflammatory Breast Cancer Registry
|
N/A | |
Recruiting |
NCT04636710 -
Refining Local-Regional Therapy for IBC
|
N/A | |
Active, not recruiting |
NCT05415215 -
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer
|
Phase 3 | |
Recruiting |
NCT04030507 -
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
|
N/A | |
Recruiting |
NCT03515798 -
Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer
|
Phase 2 | |
Completed |
NCT01583426 -
Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)
|
Phase 3 | |
Recruiting |
NCT02879513 -
Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy
|
Phase 3 | |
Completed |
NCT02199418 -
Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02623972 -
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
|
Phase 2 | |
Recruiting |
NCT00891280 -
Dose-escalation Study of Oral CX-4945
|
Phase 1 | |
Completed |
NCT00049114 -
Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04660929 -
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
|
Phase 1 |